Overview
A Phase II Study of DMP 115 to Assess Focal Liver Lesions
Status:
Completed
Completed
Trial end date:
2006-04-01
2006-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To determine the optimal dose of DMP 115 to image liver lesions and to assess whether contrast can improve the detection of focal liver lesions.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Lantheus Medical Imaging
Criteria
Inclusion Criteria:- Diagnosed with 1 but <7 focal liver lesions
- Scheduled for liver biopsy within 30 days of study
- Scheduled for CT or MR within 30 days of study
Exclusion Criteria:
- Critically ill subjects
- Subjects with right-to-left shunts